Effect of Antihypertensive Timing on Mortality and Morbidity: BedMed and BedMed-Frail Trials
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Release Date: 10/22/2024
SUMMIT Trial: Tirzepatide for Heart Failure, Preserved Ejection Fraction and Obesity
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
he SUMMIT trial compared the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Results from the trial concluded that treatment of obesity reduces major heart failure events in addition to improving health status and exercise tolerance. In this interview, Drs. Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. Podcasts | |
info_outline
Geographic Disparities in Access to Cardiologists in the United States
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Nearly one-half of US counties have no practicing cardiologists. These counties with limited access to cardiovascular care tend to be more rural and socioeconomically disadvantaged, with a greater burden of cardiovascular disease, highlighting deep geographic disparity in access to cardiovascular care in the US. In this interview, Drs. Bailey and Kim discuss “.” Related References: Cross SH, Mehra MR, Bhatt DL, et al. Rural-urban differences in cardiovascular mortality in the US, 1999-2017. JAMA 2020;323:1852–54. Loccoh EC, Nguyen A,...
info_outline
Top Takeaways from 2024: EP with Dhanunjaya Lakkireddy, MD, MBA, FACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, Dhanunjaya Lakkireddy, MD, MBA, FACC, and Alison L. Bailey, MD FACC, discuss the Top Electrophysiology (EP) Takeaways from 2024. Dr. Lakkireddy discusses climate change, high school mandated education on cardiopulmonary resuscitation, important trials impacting atrial fibrillation including PROMPT-AF and ARREST-AF, and more. Sang C, Liu Q, Lai Y, et al. Pulmonary vein isolation with optimized linear ablation vs pulmonary vein isolation alone for persistent AF: the PROMPT-AF randomized clinical trial. JAMA 2024;Nov 18:[ePub ahead of print]. ...
info_outline
Top Takeaways from 2024: General Cardiology with Andrew M. Kates, MD, FACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, Andrew M. Kates, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top General CardiologyTakeaways from 2024. Dr. Kates discusses the 2024 Perioperative Guidelines, cardiac rehab, ACC’s proposal for a new Board of Cardiovascular Medicine, and more. Bhave NM, Cibotti-Sun M, Moore MM. 2024 perioperative cardiovascular management for noncardiac surgery guideline-at-a-glance. J Am Coll Cardiol 2024;84:1970-75. Pack OR, Keys T, Priya A, et al. Is 70% achievable? Hospital-level variation in rates of cardiac rehabilitation use among medicare...
info_outline
Top Takeaways from 2024: Heart Failure with Clyde W. Yancy, MD, MACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, Clyde W. Yancy, MD, MACC, and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2024. Dr. Yancy discusses the FINEARTS-HF trial, the PREVENT calculator, the multisociety Heart Failure Guidelines, and more. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 2023;148:1982-2004. Zelniker TA, Braunwald E. Clinical benefit of...
info_outline
Top Takeaways from 2024: Preventive Cardiology with Noel Bairey Merz, MD, FACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2024. Dr. Bairey Merz discusses the and SUMMIT trials, the , and more. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; on behalf of the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32. Packer M, Zile MR, Kramer CM, et al; on behalf of the SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2024;Nov...
info_outline
Top Takeaways from 2024: Interventional Cardiology with Deepak L. Bhatt, MD, MPH, MBA, FACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, Deepak L Bhatt, MD, MPH, MBA, FACC, and Alison L. Bailey, MD FACC, discuss the Top Interventional Takeaways from 2024. Dr. Bhatt discusses the CLEAR SYNERGY, DanGer Shock, EARLY TAVR trials and more. Jolly SS, d’Entremont MA, Lee SF, et al., for the CLEAR Investigators. Colchicine in Acute Myocardial Infarction. N Engl J Med 2024;Nov 17:[Epub ahead of print]. Møller JE, Engstrøm T, Jensen LO, et al., on behalf of the DanGer Shock Investigators. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. . ...
info_outline
Top Takeaways from 2024: CV Imaging with Thomas H. Marwick, MD, PhD, FACC
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, Thomas H. Marwick, MD, PhD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Takeaways from 2024 in Cardiovascular (CV) Imaging. Dr. Marwick discusses the SCOT-HEART trial, patient-echo reports augmented by AI, tricuspid valve regurgitation, and more. Dahl JS, Julakanti R, Ali M, Scott CS, Padang R, Pellikka PA. Cardiac damage in early aortic stenosis: is the valve to blame? JACC Cardiovasc Imaging 2024;17:1031-1040. Kolossvary M, Lin A, Kwiecinski J, et al. Coronary plaque radiomic phenotypes predict fatal or nonfatal myocardial...
info_outline
Key Messages from the ACC Board of Trustees Health Equity Action Plan
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Disparities in health care disproportionally impact under-resourced and minority communities resulting in excess mortality and morbidity. Decreasing and eliminating these disparities will improve health statistics for all. The American College of Cardiology's (ACC) Health Equity Task Force is demonstrating its commitment to health equity through championing the improvement of patients’ lived experiences, population health, and clinician well-being while reducing health care costs—the Quadruple Aim of Health Equity. In this interview, Drs. Richard Chazal and Paul Douglass...
info_outline
How Has Antithrombotic Therapy for PAD Changed Over the Last Decade?
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack, stroke, bleeding risk, and leg disease, which could lead to acute limb ischemia and amputation. Blood thinning medications (antithrombotic therapy) have shown rapid evolution and broad benefits and novel approved strategies that improve outcomes are available. It is imperative that clinicians select appropriate patients for use and consider the complex situations for management. In this interview, Drs. Cindy Grines and Marc Bonaca discuss . Podcasts |...
info_outlineThe BedMed and BedMed-Frail trials assisted in providing clarity as to the daily timing of prescribed blood pressure medication. The two trials, one conducted in a general primary-care population and the other among nursing-home residents, determined no difference in major cardiovascular events or safety between blood pressure (BP) medication distribution in the evening or morning.
In this interview, Drs. Anthony DeMaria and Scott Garrison review the BedMed and BedMed-Frail trials findings which proved the emphasis to patients is taking BP medication when they are least likely to forget, irrelevant of time of day.
References:
-
Pigazzani F, Dyar KA, Morant SV, et al. Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) study. EClinicalMedicine 2024;72:102633.
-
Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 2022;400:1417-25.
-
Hermida RC, Crespo JJ, Dominguez-Sardina M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2020;41:4565-76.
-
Hermida RC, Ayala DE, Fernandez JR, et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013;30:280-314.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL